Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Blood Cancer J · 2016 · PMC4817104 · PMID 26967821

Europe PMC DOI

hedged sentence

0.0490

closest p · 1.0× alpha

0.0490

boldest claim

The sentences

borderline significanceP =0.049actually significant

ORR for patients with del(17p) was lower than for those without deletions with borderline significance, using Fisher's exact test (21.7% vs 47.1%, P =0.049; odds ratio: 0.31; 95% confidence interval: 0.10 and 0.93).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.